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ABSTRACT: Several studies analyzing the immune responses in
patients with cow’s milk allergy (CMA) have used T-cell lines or
T-cell clones that require prolonged in vitro cell culturing and may
result in a switched cell phenotype and function. We investigated
immune responses to beta-lactoglobulin (b-LG) in peripheral blood
mononuclear cells after a short in vitro antigen stimulation in chil-
dren with acute CMA (both IgE-mediated and non-IgE-mediated
forms) and in those who outgrew an IgE-mediated CMA. Healthy
controls were also investigated. Peripheral blood mononuclear cells
were assayed for IL-13, IFN-, IL-4, and IL-10. Although b-LG
induced a cytokine production and/or cell proliferation almost in all
children, included healthy controls, differences were observed among
the four groups. Children with IgE-mediated CMA had a marked
Th2-response, with high IL-13 production and proliferation, but low
IFN-; by contrast, children with non-IgE-mediated CMA produced
no, or very low, IL-13 and cell proliferation. Children, who outgrew
CMA, showed a shift to a Th1-response, with reduced IL-13 and
increased IFN-. IL-10-responses were high in all groups, with the
highest level in healthy children; by contrast, IL-4 was undetectable
in all children. This study highlights the use of shortly stimulated
peripheral blood cells to investigate the food-induced immune re-
sponses. (Pediatr Res 70: 549–554, 2011)
Allergy to cow’s milk proteins (CMP) is one of the mostcommon food allergies (FA) in the developed coun-
tries elicited by an IgE- or non-IgE-mediated mechanism
(1,2). The major allergens of cow’s milk (CM) are beta-
lactoglobulin (b-LG) and alpha-S1-casein, as indicated by
large population studies (3). These proteins are also highly
resistant to proteolysis by gastrointestinal enzymes, result-
ing in large peptides at the site of mucosal immune system
with implications for immune reactivity and cow’s milk
allergy (CMA) emergence (4).
Profile of immune responses to the main CMP is not
completely understood, particularly in those patients affected
by gastrointestinal, non-IgE-mediated, forms of CMA (2).
Furthermore, a consistent number of the studies investigating
the immune responses to CMP, and to food allergens in
general, have used T-cell lines or T-cell clones, mostly de-
rived from peripheral blood mononuclear cells (PBMCs)
(5–12). Albeit these are powerful techniques to investigate
immune response to several antigens, and to define the stim-
ulatory sequences in complex antigenic proteins, manipulation
can occur in long-term cell cultures that could result in
alteration of cell phenotypes and functions. T cells producing
IL-4 and IL-13 (Th2-phenotype) were described in children
with acute IgE-CMA (6), whereas CMP-specific, IFN- re-
leasing cells (Th1-skewed phenotype) were described in in-
fants without CMA (6). Marked T-cell proliferation to CMP
occurs in the great majority of subjects, independently of a
positive CMA diagnosis (13).
Children with CMA (either IgE- or non-IgE-mediated)
spontaneously outgrow allergy (14), rendering this alimentary
disorder an important model to study the mechanisms that
mediate the immune tolerance to CMP and to food antigens in
general. IL-10-producing Tr1 and CD4CD25 regulatory T
(Treg) cells have been suggested to play a key role in toler-
ance acquisition in CMA children (5,15). Although it has been
reported that Treg cells are not impaired in their suppressive
function during allergic diseases (16), and both healthy and
allergic individuals exhibit all three allergen-specific T-cell
subsets (Th1, Th2, and Treg), it is likely that allergic condition
results from an inappropriate balance between Treg and T-ef-
fector responses (13,17–19).
In this study, we comparatively analyzed the profile of
immune reactivity to b-LG in four different groups of children:
1) with IgE-mediated CMA; 2) with non-IgE-mediated CMA;
3) who have outgrown IgE-mediated CMA; and 4) healthy
controls with no history of any FA. IL-13, IL-4, IL-10, IFN-,
and cell proliferation were evaluated in fresh PBMCs after a
short in vitro stimulation with b-LG, thus avoiding prolonged
cell culturing and undesired cell manipulation. The HLA
restriction and the role of IL-10 in controlling the peripheral
immune responses to b-LG were also investigated.
PATIENTS AND METHODS
Study subjects. Twenty-eight patients with a diagnosis of CMA were
enrolled: 14 with IgE-mediated CMA and 14 with non-IgE-mediated CMA.
They had been on elimination diet for 10.2 mo (range, 6–16 mo) and 8.9 mo
(range, 6–14 mo), respectively. For comparison, nine children who have
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outgrown IgE-mediated CMA and consumed CM regularly since at least 6 mo
and 14 healthy controls who consumed at least one full cup of CM daily, were
also evaluated. Exclusion criteria were chronic systemic diseases, congenital
cardiac defects, active tuberculosis, autoimmune diseases, immunodeficiency,
chronic inflammatory bowel diseases, celiac disease, cystic fibrosis, metabolic
diseases, or malignancy. Control children were enrolled among subjects
visiting the Center for routine examinations or for minimal surgical proce-
dures. These children met the same inclusion and exclusion criteria, except
that they did not have a history of FA, neither of atopy, and were serum
negative for CMP-specific IgE. Main demographic and clinical characteristics
of the enrolled children are reported in Table 1. The diagnosis of CMA was
obtained in our Department assessing: 1) clinical history; 2) the results of
allergen-specific IgE titers, skin prick, and patch tests; and 3) the result of the
oral food challenge, as previously described (20). All food challenges were
performed within 3 mo before study entry, in a double-blind placebo-
controlled manner (DBPFC), and took place in the outpatients clinic of our
Department on two separate days with a 1-wk interval. The results were
assessed by two experienced pediatric allergists. Briefly, every 20 min, fresh
pasteurized CM (0.1, 0.3, 1, 3, 10, 30, and 100 mL) containing 3.5% fat or
placebo (Neocate, Nutricia Italia SpA) were administered. Study subjects
were scored for nine items divided into four main categories (general, skin,
gastrointestinal, and respiratory) on a 0- to 3-point scale (0, none; 1, light; 2,
moderate; and 3, severe). If both investigators independently scored any item
at level 3 or 2 (or more) items at level 2, the test result was considered
positive. Parents of infants taking an antihistamine were advised to withhold
the treatment for 72 h before and during the challenge. The child was
observed for 2 h after the final dose and then discharged. The tested formula
(100 mL/d) was given by the parents at home for 7 d. If any symptoms
occurred during this period, the patients returned to the outpatient clinic on
the same day. On d 7, all infants were examined and the parents interviewed
at the Department. An oral food challenge was repeated every 6 mo until the
appearance of oral tolerance. The results of allergic screening tests and oral
food challenge were registered into a specific clinical chart. Approval for the
study was obtained from the Ethics Committee of the Medical School at the
University of Naples “Federico II,” and written informed consent was ob-
tained from parents of each child enrolled in the study.
Isolation of PBMCs and functional assays. All children were evaluated in
stable clinical conditions without fever or any acute illness in the last 3 wk.
At the enrollment of each study subject, a venous blood sample (5–8 mL) was
collected in a heparinized tube. PBMCs were isolated from blood samples by
Ficoll gradient. After washing, cells were resuspended in X-VIVO containing
5% heat-inactivated, human AB sera (BioWhittaker-Lonza) at a density of
2  105/200 L/well for functional assays. Cells were stimulated with b-LG
(100 g/mL), BSA (100 g/mL), or phytohemagglutinin (PHA; 2 g/mL).
IFN-, IL-4, and IL-10 were analyzed by a 36–40 h enzyme-linked immu-
nosorbent spot (ELISPOT) assay, or by 48 h ELISA, as previously described
(21). The levels of IL-13 were evaluated in cell supernatants by a 48 h ELISA
assay. ELISPOT results are shown as net spot-forming cells (SFC; number of
SFC detected in the presence of antigen minus SFC detected with the medium
alone) on the total of cells plated. Sensitivity of ELISA assays was as follows:
125 pg/mL for IL-13, 63 pg/mL for IFN-, and 9 pg/mL for IL-4. Results are
shown as net of cytokine concentration. In the experiments with blocking
anti-IL-10R and anti-DR/DQ MAbs, PBMCs were preincubated for 10 min
with 10 g/mL of each MAbs, before the addition of antigens. All experi-
mental points were done in duplicates.
Proliferation assays. PBMCs were incubated for 6 d in the presence or
absence of indicated antigens. The cultures were thereafter pulsed with 0.5
Ci [3H]-thymidine (Amersham-Pharmacia, Milan, Italy) and incubated for
additional 9 h before the [3H] incorporated in the DNA was measured by
liquid scintillation counting (TopCount, Packard, Canberra). Results were
shown as stimulation index (SI), i.e. cpm in cells stimulated with antigens
divided by cpm in cells stimulated with medium alone.
Antigens and antibodies. b-LG and BSA were purchased from Sigma
Chemical Co. (Sigma Chemical Co.-Aldrich, Milan, Italy). Antigens were
tested for lipopolysaccharide (LPS) content by the Limulus Amebocite Lysate
kit (BioWhittaker-Lonza, Basel, Switzerland) according to the manufacturer’s
instructions. LPS content is expressed as endotoxin units (EU)/mg of protein
(1 EU corresponds approximately to 100 pg of LPS). PHA was purchased
from Roche (Milan Italy). Anti-IL-4R blocking MAb (MAb) was from R&D
System (Milan, Italy). Both purified and biotinylated anti-IFN-, IL-4, and
IL-13 MAbs were from e-Bioscience (San Diego, CA); specific capture and
detection anti-IL-10 antibodies were from Endogen (San Diego, CA); anti-DQ
MAb (clone SPV-L3) from Biodesign International (Saco, ME); anti-IL-10R
(clone 3F9) and anti-DR MAbs (clone L243) were purchased from PharMin-
gen-BD (Milan, Italy).
Statistics. Data are presented as median (interquartile range). Comparison
between groups was performed by nonparametric two tailed Mann-Whitney U
test using SPSS version 16.0 for Windows (SPSS, Inc., Chicago, IL). The
p  0.05 was considered significant.
RESULTS
Cytokine Production Profile of Peripheral Blood Cells in
Response to b-LG. To investigate the cytokine and prolifera-
tive response elicited by the ingestion of CM in children with
a positive history of CMA, we have stimulated freshly isolated
PBMCs with b-LG, one of the main allergen of CMP or with
BSA as control protein. Cell activation was evaluated after 2 d
(for cytokine production) or 6 d (for cell proliferation): this
procedure allowed us to monitor secondary immune re-
sponses, most likely primed in vivo after allergen exposure.
Because we have analyzed PBMCs’ immune reactivity either
Table 1. Main demographic and clinical characteristics of the study population
Healthy
controls
IgE-mediated
CMA
Non-IgE-mediated
CMA
Tolerant, ex
IgE-mediated CMA
N 14 14 14 9
Male, n (%) 9 (64.2) 11 (73.3) 8 (57.1) 8 (88.8)
Age in months, median (range) 39.2 (6–81) 40.4 (10–66) 26.1 (6–89) 49.7 (19–138)
Age in months at the onset of food allergy-related
symptoms: median (95% CI)
— 9.8 (7.2–14.7) 7.4 (6.7–11.7) 8.5 (5.9–12.8)
Symptoms*
Eczema — 10 (71.4) 9 (64.2) 9 (100)
Angioedema-urticaria — 8 (57.1) 0 (0.0) 7 (78)
Gastrointestinal — 8 (57.1) 14 (100) 5 (55.5)
Laryngospasm — 1 (7.1) 0 (0.0) 0 (0.0)
Anaphylaxis — 2 (14.2) 0 (0.0) 0 (0.0)
Total serum IgE (kU/l) (mean  SD)† 0.35 196.9  140 14.7 15.9 57.9 33.4
Cow’s milk-specific IgE (kU/l) (mean value  SD)† 0.35 21.1  17.7 0.5 0.7 3.1 2.7
Cow’s milk SPT weal (mm) (mean value  SD) — 6.5 1.2 — 2.2  1.4
Cow’s milk APT positive, n (%) — — 10 (71.4) —
* Symptoms are referred to the time of CMA diagnosis.
† Total serum IgE and cow’s milk-specific IgE were measured using a commercially available kit (CAP-RAST, Pharmacia Diagnostics AB, Uppsala, Sweden).
The positive cutoff value was 0.35, all healthy controls showed results below this cutoff value.
APT, atopic patch test; kU, kilo units; SPT, skin prick test.
—, not applicable.
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in individuals with CMA (IgE- or non-IgE-mediated), and in
children who became tolerant, or who have never experienced
an allergic reaction to CMP, and in which the immune re-
sponses are supposed to be weak or not expected at all, we
have chosen as read-out the very sensitive ELISPOT assay to
detect antigen-specific cellular response for IFN-, IL-4, and
IL-10. Instead, IL-13 was analyzed by ELISA because of the
technical limitations we had in studying this cytokine by
ELISPOT.
IL-13. We aimed to investigate whether IL-13 is produced
by PBMCs of allergic children in response to b-LG. As shown
in Figure 1, the IL-13 production was significantly increased
in patients with IgE-mediated CMA: median (interquartile
range) 785.5 (257.1–1274.2) pg/mL, compared with subjects
with non-IgE-mediated CMA: 37.0 (0.0–198.25) pg/mL or
with healthy controls: 117.1 (46.1–657.8) pg/mL (p  0.015
and p  0.05, respectively). Although two tolerant patients
produced relatively high amount of IL-13 in response to b-LG,
the amount of this cytokine detected in clinically tolerant
children, 232.0 (18.7–647.5) pg/mL, was much less than the
level in children on acute disease, albeit the difference did not
reach a statistical significance. The stimulation with BSA did
not induce significant IL-13 production in any of the four
groups analyzed, except few subjects who resulted responsive
in control and in tolerant groups.
IFN-. Overall, we found very low number of IFN--
producing cells in PBMCs in response to a short stimulation
with b-LG in all four groups analyzed: median (interquartile
range) of net IFN--SFC/2  105 cells: 5.5 (1.3–27.0). Chil-
dren who recovered an IgE-mediated CMA displayed the
highest number of IFN--producing cells: 41.0 (21.0–47.5),
significantly higher compared with children with acute IgE-
CMA: 1.0 (0.0–3.6), p  0.05, (Fig. 2A). Low IFN--
responses to b-LG were observed in non-IgE-allergic children,
except few subjects: 5.0 (1.8–34.4). By contrast, the control
protein BSA did not recall any substantial IFN--response.
Because children with IgE-mediated CMA displayed, as a
whole group, a very low number of IFN--secreting cells, and
conversely a very high IL-13 production upon b-LG stimula-
tion, to better compare these two cytokine responses, we
analyzed the level of IFN- in PBMCs supernatants by ELISA
in 12 children, previously analyzed by ELISPOT (Fig. 2B). In
10 of 12 children, the production of IFN- resulted very low
(below 150 pg/mL), if compared with the level of IL-13,
(range, 250.0–3300.0 pg/mL), confirming the trend observed
in the IFN--ELISPOT (Fig. 2A).
IL-4. In this study, we were not able to detect any signifi-
cant IL-4 production in peripheral blood in response to b-LG
or BSA, either by ELISPOT or ELISA (data not shown). No
better results were obtained after optimizing the assay through
the use of an antibody blocking the IL-4 receptor (data not
shown). A defect in either IL-4 production in PBMCs or in
IL-4 assay procedures can be excluded because PBMCs incu-
bated with the polyclonal activator PHA secreted high level of
this cytokine (data not shown).
IL-10. IL-10-producing cells were consistently detected in
PBMCs of all groups after stimulation with b-LG and at very
high frequencies: median (interquartile range) of net IL-10-
Figure 1. IL-13 production of PBMCs in response to b-LG and BSA.
Antigen-specific production of IL-13 was evaluated in PBMCs of 13
healthy controls (ctr), 14 children with IgE-mediated CMA (IgE), 14
children with non-IgE-mediated CMA (non-IgE), and 8 children who have
outgrown an IgE-mediated CMA (tolerants). Fresh PBMCs (2  105/well)
were stimulated with b-LG and BSA (100 g/mL), and after 48 h, the level
of IL-13 was measured in cell supernatants by a sandwich ELISA.
Horizontal bars represent the median values obtained within each group.
Significance was determined using the nonparametric Mann-Whitney U
test comparing allergic or tolerant groups with healthy controls or between
them. **p  0.015, *p  0.05.
Figure 2. IFN- production of PBMCs in response to b-LG and BSA. (A)
IFN--secreting cells were evaluated in peripheral blood of children with
CMA (8 IgE- and 12 non-IgE-mediated) of 5 tolerants and of 9 healthy
controls on allergen stimulation; 2  105 PBMCs were stimulated with b-LG
and BSA (100 g/mL) and IFN--producing cells detected by 36–40 h
ELISPOT-assay. Horizontal bars represent the median value within each
group (*p  0.05). (B) IFN- and IL-13 production in response to b-LG
stimulation (100 g/mL) was analyzed in PBMCs from 12 children with
IgE-mediated CMA. Cytokine levels were measured in cell supernatants as
described in Figure 1.
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SFC/2  105 cells: 915.0 (503.0–1187.0). Healthy children
showed the highest number of IL-10-producing cells in re-
sponse to b-LG: 1333.0 (815.0–1755.5; Fig. 3), and similarly
to IFN-- and IL-13-responses, IL-10-producing cells were
not detectable against BSA in any of the four groups analyzed,
if excepted few subjects.
To dissect if LPS contamination found in b-LG prepara-
tions, 20 EU/mg of protein, could affect the cytokine pro-
duction in our study population, we performed preliminary
experiments using PBMCs from adult healthy donors and
escalating dose of LPS. We found that LPS at the concentra-
tion detected in our antigen samples induced the production of
IL-10, while no IL-4, IL-13, and IFN- were produced. Fur-
thermore, LPS contamination accounted for only a part of the
high IL-10 production observed in PBMCs (data not shown).
Proliferative Response of PBMCs to b-LG. The rate of
PBMC proliferation to b-LG was analyzed 6 d after the
allergen stimulation of PBMCs by looking at [3H]-thymidine
incorporation in the DNA. When we looked at the prolifera-
tion in each single subject (selecting a SI  3, as cutoff for
positive response), we found that subjects responsive to b-LG
were present in all groups, including the healthy donors.
Nevertheless, children with IgE-mediated CMA showed the
highest cell proliferation rate: median (interquartile range) 7.0
(3.0–9.8), compared with controls: 2.4 (1.8–4.5) and with
patients with non-IgE-mediated CMA: 2.6 (1.9–3.9; p 0.05,
Fig. 4).
PBMCs Response to b-LG is HLA-Class II-Restricted and
Is Increased by Blocking IL-10. We next evaluated whether
HLA-class II restricts the PBMCs responses to b-LG. Because
of the limited availability of blood samples, the HLA restric-
tion was assessed by using a cocktail of antibodies blocking
the HLA-DQ and HLA-DR molecules in four IgE-mediated
and in five non-IgE-mediated allergic children. As shown in
Figure 5A, the proliferative responses to b-LG were signifi-
cantly reduced in the presence of the neutralizing antibodies in
all patients analyzed (p 0.0001). These results indicated that
b-LG specifically induced proliferation of circulating T cells
and that HLA-DQ/DR molecules play a substantial role in
recalling secondary cell responses in peripheral blood of CMA
children.
To further address whether IL-10, found highly up-
regulated in PBMCs in the great majority of subjects analyzed,
might have a regulatory effect, we stimulated cells from both
allergic and tolerant children with b-LG in the presence or
absence of antibody blocking the IL-10 receptor. Remarkably,
the blocking of IL-10 activity caused an increase of cell
proliferation to b-LG ranging from 1.3- to 7.6-folds compared
with the responses of not treated cells (p  0.05; Fig. 5B).
DISCUSSION
This study shows that following a brief in vitro stimulation,
b-LG-specific cell responses can be recalled in peripheral
blood of children affected by CMA and of tolerant or nonal-
lergic, healthy children. Although b-LG stimulation induced
an immune reactivity in PBMCs of the great majority of
analyzed children (93% up to 100% of subjects showed a
positive response, as cytokine secretion and/or cell prolifera-
tion), differences among the groups occurred. Children with
IgE-mediated CMA produced significantly higher IL-13 com-
pared with healthy children and with children with non-IgE-
mediated CMA. Conversely, tolerance to CMP was associated
with a marked reduction of IL-13 production and a concom-
itant increased frequency of b-LG-specific, IFN--releasing
cells. Children with IgE-mediated CMA showed the highest
rate of proliferation to b-LG. This suggested that an immediate
clinical reaction to milk ingestion, typical of IgE-mediated
allergy, might be associated with a prompted in vivo T-cell
proliferation to b-LG, and the marked reduction of T-cell
Figure 3. IL-10 production of PBMCs in response to b-LG and BSA.
Antigen-specific, IL-10-secreting cells were evaluated in PBMCs from CMA
children (11 IgE- and 13 non-IgE-mediated), 8 tolerants, and 10 healthy
controls; 2  105 PBMCs were stimulated with b-LG or BSA (100 g/mL)
and assayed by ELISPOT after 36–40 h. Horizontal bars represent the
median value within each group. *p  0.05.
Figure 4. Proliferative response of PBMCs to b-LG. b-LG-specific, prolif-
erative response in PBMCs from CMA children (14 IgE- and 14 non-IgE-
mediated), from 9 children who outgrew IgE-CMA, and from 14 healthy
controls. PBMCs were incubated with b-LG as reported in Figure 1, and the
rate of cell proliferation was determined 6 d after by labeling cells with 0.5
Ci [3H] thymidine/well. Values are shown as SI. Proliferative responses
were considered positive when SI was 3. Horizontal bars represent the
average SI among patients of each group. The broken line indicates the cutoff
value for positive response. *p  0.05.
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proliferation to b-LG in children who acquired tolerance to
CMP corroborates this finding.
Collectively, the profile of immune responses to b-LG in
freshly isolated PBMCs are consistent with previous reports
done with long-lasting T-cell cultures and showing a polarized
Th2-responses, with a marked IL-13 production, in acute
IgE-mediated FA, and a Th1-skewed cytokine pattern, with
IFN- production, in non-IgE-mediated forms (5,6). We were
not able to detect any specific production of IL-4 in any of
analyzed subjects and this was in contrast with previous
reports (5,12). This discrepancy can be explained by the fact
that our experimental design is not sufficient to recall a
detectable IL-4 response in peripheral blood, being this lower
than the sensitivity threshold of ELISPOT/ELISA assays we
have used.
The acquisition of tolerance in children who had an IgE-
mediated form of CMA was associated with a profile of
peripheral blood secondary responses characterized by a si-
multaneous reduction of IL-13 production and increased fre-
quency of IFN--releasing cells. Similarly, recent studies
showed a Th1-like cytokine production profile in children
after the complete resolution of peanut- (17) or egg-sensitized
children (22).
Studies involving children have profound ethical restric-
tions and, in the case of our study, very limited blood samples
were available. As a consequence, we were not able to further
characterize the phenotype of peripheral blood cells reacting
to b-LG. We found that proliferative responses were strongly
reduced when blocking HLA-DQ and -DR molecules, in
agreement with previous studies showing that allergens pre-
dominantly activate major histocompatibility complex-class II
restricted CD4 T cells (3,23,24). Furthermore, our findings
are in line with previous reports demonstrating the presence of
food-specific T lymphocytes also in nonallergic, healthy sub-
jects (13,17,18,23,25). In this respect, it has been suggested
that food protein-specific T cells may be produced as part of
a normal immune response, and their presence is not restricted
to a clinical manifestation of FA. Tsuge et al. (13) reported
that the presence of CMP-specific, T-cell responses does not
produce CMA per se, because either Th1, Th2, and Treg T cell
clones reactive to allergens have been described in both
healthy and allergic subjects. This suggests that the onset of
allergic disease strictly depends on a delicate balance between
effector and regulatory cell subtypes. Interestingly, a recent
study reported that b-LG is able to activate both Treg and Th2
cells in PBMCs of CMA allergic children (26).
Although immune mechanisms underlying the acquisition
of tolerance to food allergens remain poorly understood,
several studies reported a key role of CD4CD25 Treg cells
in children who outgrew CMA (15,16). In addition, it has been
suggested that also IL-10-producing Tr1 cells have an impor-
tant role in maintaining tolerance to food antigens (21,27). We
found a marked production of IL-10 in PBMCs on stimulation
with b-LG in all four groups analyzed, and nonallergic healthy
children displayed the highest IL-10 level. Although we can-
not exclude that the high IL-10 production to b-LG observed
in all four analyzed groups could be partially because of an
LPS-like activity of this allergen (28,29), it remains interest-
ing that healthy children showed the highest number of IL-
10-producing cells and that IL-10 was able to down-regulate
the PBMCs’ proliferative response to b-LG stimulation.
Collectively, our findings on the profile of immune response
detected in shortly stimulated peripheral blood cells well agree
with previous studies done with long-term T-cell lines or
clones (3,5,6) and support the use of fresh PBMCs to inves-
tigate the food-induced immune responses.
Understanding the immune mechanisms that underlie the
onset of CMA, or mediate the tolerance in patients who have
outgrown CMA, offers promise for a more accurate prognosis.
Furthermore, possible intervention strategies could be more
efficiently designed. Additional efforts are required to define
the profile of immune responses occurring in the allergic
condition or associated with the acquired immune tolerance to
CMP. It is evident that the panel of immune markers investi-
gated in this study have to be expanded, particularly it would
be interesting to evaluate the role of Th17 and Th22 subsets in
immune response in CMA, as demonstrated for other common
allergies (30,31). The definition of the repertoire of immune
responses detected with rapid in vitro assays would also offer
a valid tool to monitor the evolution of one of the most
frequent food allergies in childhood.
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Figure 5. Proliferative response of PBMCs to b-LG in the presence of
blocking MAbs. Effect of anti-HLA-class II antibodies (A) and of anti-IL-10
receptor (B) MAbs on the proliferative response to b-LG in PBMCs from
CMA allergic or tolerant patients. Proliferative responses, evaluated as SI, to
b-LG in the presence of indicated blocking antibody (f) are normalized with
the response observed with b-LG alone (SI  1, ).
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